Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate

Valneva and Pfizer today announced initiation of study VLA15-221. The VLA15-221 study builds on previous positive Phase 2 studies, incorporates new dose regimens and is anticipated to be the final Phase 2 study readout before a decision to progress into pivotal Phase 3 studies.

Read more